IL-2: The First Effective Immunotherapy for Human Cancer

By S. Rosenberg. Journal of Immunology, 2014

1,162 citations recorded by the source corpus.

The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding αβ TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/17141d82214206b4fd2d50e03f5799592b67a633

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. Jie Yang
5. R. Sherry
6. U. Kammula
7. M. Hughes
8. J. Wunderlich

In Oncology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. Jie Yang
5. R. Sherry
6. U. Kammula
7. M. Hughes
8. J. Wunderlich

Citations in the corpus

• SARS-CoV-2 infection: The role of cytokines in COVID-19 disease (2020, neutral): “IL-2 plays a key role in the proliferation of T cells and in the generation of effector and memory T cells [61].”
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014, background): “(19)], and 18 of the 20patientswithmelanoma treated in this trial receivedprior highdose IL-2 treatment.”